Titan Pharmaceuticals INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Titan Pharmaceuticals reported significantly reduced net losses and improved cash flow, while progressing towards a reverse merger with TalenTec and resolving Nasdaq listing compliance issues.
10-Q: Titan Pharmaceuticals Reports Q1 2025 Results, Focuses on Strategic Merger and Nasdaq Compliance
Titan Pharmaceuticals reported a net loss for Q1 2025, continues to pursue a merger with TalenTec, and addresses Nasdaq compliance concerns.
Titan Pharmaceuticals reported its Q3 2024 financial results, highlighting a net loss and ongoing strategic transition, including a planned merger with TalenTec.
Titan Pharmaceuticals reported its Q2 2024 results, highlighting a strategic shift towards product development and significant leadership changes.
10-Q: Titan Pharmaceuticals Reports Q1 2024 Results, Navigates Leadership Changes and Strategic Shifts
Titan Pharmaceuticals reported a net loss of $1.1 million for Q1 2024, alongside leadership changes and ongoing strategic shifts following the sale of key assets.